Here we combined and curated DNA sequencing and RNA-seq datasets from HPV-positive CESC and HNSCC tumors and compared them with novel “in-house” datasets of common fragile sites defined by FANCD2 ChIP-seq, and enhancers and super-enhancers defined by Brd4 and H3K27ac ChIP-seq in cervical carcinoma-derived cells. This evidence concerns the gene FANCD2 and cervical carcinoma.